Apeironpharma - Company finances
|
EUR
|
2018
From: 2018-11-19
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | 453,871 | 393,914 | 502,073 | 537,218 | 501,278 | 543,051 |
| Profit before tax | 0 | 0 | 52,719 | 44,751 | 51,886 | 78,849 | 74,743 | 84,023 |
| Net profit | 0 | 0 | 44,811 | 38,038 | 44,103 | 67,022 | 63,532 | 70,579 |
| Equity | 2,500 | 2,500 | 46,416 | 84,454 | 128,557 | 214,399 | 277,931 | 348,510 |
| Liabilities | 0 | 0 | 75,227 | 37,002 | 71,475 | 366,388 | 305,251 | 205,755 |
| Non-current assets | 0 | 0 | 46,455 | 39,793 | 89,293 | 444,776 | 533,777 | 506,166 |
| Current assets | 2,500 | 2,500 | 82,427 | 97,301 | 110,739 | 151,159 | 84,694 | 61,543 |
| Total assets | 2,500 | 2,500 | 128,882 | 137,094 | 200,032 | 595,935 | 618,471 | 567,709 |
|
Taxes paid
|
||||||||
| Social insurance contributions | - | - | - | - | - | 1,660 | 2,103 | 2,860 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | -13.2% | +27.5% | +7.0% | -6.7% | +8.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 0.0% | 34.8% | 27.7% | 22.0% | 11.2% | 10.3% | 12.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 0.0% | 96.5% | 45.0% | 34.3% | 31.3% | 22.9% | 20.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | 9.9% | 9.7% | 8.8% | 12.5% | 12.7% | 13.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 11.6% | 11.4% | 10.3% | 14.7% | 14.9% | 15.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 1.6 | 0.4 | 0.6 | 1.7 | 1.1 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 453,871 | 139,030 | 130,977 | 134,305 | 125,320 | 135,763 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Apeironpharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-05-17 | 2022-05-31 | 1.00 |
Apeironpharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-21 | 2026-02-21 | 0.06 |
| 2025-09-19 | 2025-09-23 | 986.78 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Apeironpharma, UAB (code 304953344) is a Private Limited Liability Company engaged in wholesale of fruit and vegetables. In 2025, the company generated revenue of €543.1K, up 8.3% year on year and 1.1% over two years. Net profit reached €70.6K, with a profit margin of 13.0%, slightly above the 12.7% recorded in 2024 and 12.5% in 2023. The three-year trend shows a temporary decline in revenue in 2024 followed by a recovery in 2025, while profitability remained stable and improved modestly. Balance sheet indicators also strengthened in equity terms: equity increased to €348.5K in 2025 from €277.9K in 2024 and €214.4K in 2023, while liabilities fell to €205.8K. Total assets were €567.7K in 2025, compared with €618.5K a year earlier and €595.9K in 2023. The company reported ROE of 20.2%, ROA of 12.4%, debt-to-equity of 0.59, and asset turnover of 0.96x. Revenue per employee stood at €135.8K, with profit per employee of €17.6K.